AnaptysBio: Legal Wins Could Flip the Royalty Waterfall - A Tactical Long

Hook / Thesis

The Delaware Chancery Court gave AnaptysBio a procedural win on 04/24/2026 when it dismissed Tesaro's anticipatory breach claim, a ruling that narrows Tesaro/GSK's playbook and increases the odds that Anaptys can press for a contractual remedy tied to Jemperli royalties. That procedural win, combined with concentrated ownership and a float of roughly 27.8 million shares, creates a setup where favorable trial outcomes or settlement headlines could rapidly re-rate the stock.

I'm recommending a tactical long: enter at $52.00 with a stop at $45.00 and a target of $75.00. The thesis is binary-ish - litigation outcomes drive material cash flows (royalties or reversion) that the market is underpricing today. This trade is explicitly dependent on continued favorable legal momentum and market recognition that Anaptys’ claims have value.

Why the market should care - business + fundamental driver

AnaptysBio is a clinical-stage biotech focused on antibody therapeutics and proprietary SHM discovery technology, but the near-term valuation hinge is not R&D readouts alone - it's the economics attached to Jemperli (dostarlimab). The collaboration agreement with Tesaro/GSK includes royalty mechanics that, under certain contractual breaches, could revert or produce outsized damages for Anaptys. That potential royalty waterfall is the single most tangible value lever on the balance sheet today.

From a capital structure standpoint, the stock carries a market capitalization of about $1.54 billion and enterprise value near $1.294 billion. Earnings are negative (EPS around -$0.90), and traditional multiples are stretched in places: price-to-book above 120x and price-to-sales roughly 6.6x. Those are signs the market is paying for optionality - either pipeline upside or deal-related payouts. If the litigation results in material royalties or a reversion of Jemperli rights, those multiples would look cheap; if not, downside is obvious.

Supporting numbers

• Current price is trading around $52.50 after a pullback from a 52-week high of $72.36 (05/05/2026) and a 52-week low of $12.53 (09/16/2025).
• Market cap: $1.5426 billion; enterprise value: $1.2944 billion.
• Cash on the balance sheet (per share metric shown) ~ $5.96; free cash flow most recently ~$4.41 million.
• Short interest has been meaningful: roughly 4.999 million shares short as of 07/15/2026, which equates to ~5.86 days to cover on current average volume - a setup for a quick squeeze on positive headlines.
• Technicals: RSI ~41 and MACD showing bearish momentum, indicating the stock has room to move higher if legal news flips momentum; short-volume data shows active shorting in recent sessions.

Valuation framing

Right now the market is implicitly pricing Anaptys as a company with an expensive R&D pipeline and some legal option value. A $1.54 billion market cap implies the market is giving limited present value to Jemperli-linked royalties unless they are made explicit by court remedies or settlement. If the litigation results in a reversion or significant damages tied to lost royalties, two valuation outcomes are plausible:

• Partial recovery: a settlement or damages award that assigns a multi-year royalty stream to Anaptys would likely be discounted at biotech risk rates, yet even a conservative multi-year royalty could justify a high-single-digit to low-double-digit percentage re-rate from current pricing.
• Full reversion or large damages: if Anaptys succeeds in proving material breach and the contract remedies result in reversion or recurring royalties, that cash flow would meaningfully de-risk the equity and compress pricing multiples (P/S and EV/S), supporting a materially higher market cap.

Comparables are tricky because this is litigation-driven value rather than a typical earnings story. Think of the current market cap as a bet on pipeline optionality plus a legal option; the trade targets a re-pricing of that option into hard cash flows or clarified economics.

Catalysts (events to watch)

• Follow-up court filings, rulings and transcripts from the Delaware Chancery Court related to the July trial window (scheduled 07/14/2026 - 07/17/2026). Any ruling or clear path toward damages/reversion is a major positive.
• Settlement chatter or official announcements from Tesaro/GSK - even a partial settlement would materially reduce uncertainty and likely trigger a re-rate.
• Quarterly updates or investor communications that quantify potential royalty claims or provide legal expense guidance - management transparency can shorten the time to market recognition.
• Short interest dynamics and daily short-volume prints - a sustained drop in borrow or a squeeze on elevated short interest could amplify price moves on good news.

Trade plan

Recommendation: Long ANAB.

• Entry price: 52.00
• Stop loss: 45.00
• Target price: 75.00
• Time horizon: long term (180 trading days) - I expect legal resolution, potential appeals and follow-on commercial/financial recognition will play out over months, not days. A 180-trading-day horizon gives time for a definitive legal outcome to be digested and for the market to re-price the equity accordingly.

Rationale for sizing and horizon: the litigation is the driver; legal outcomes take time and can be noisy. Enter at $52.00 to capture current pullback momentum while keeping a $45.00 stop to protect against a negative surprise (e.g., an adverse ruling or an unexpected settlement unfavorable to Anaptys). The $75.00 target sits above the recent 52-week high and would reflect meaningful recognition of the Jemperli economics or a large settlement/damages award.

Risks and counterarguments

• Unfavorable legal outcome - the most obvious risk: if the court ultimately sides with Tesaro/GSK, Anaptys could see royalties reduced or lose claims entirely, which would likely send the stock lower. This trade is contingent on legal upside.
• Settlement on terms unfavorable to Anaptys - a settlement that preserves Tesaro's royalty economics but gives Anaptys only modest compensation would limit upside and could be judged a draw by the market.
• Binary headline risk - court rulings, motions, or leaks can move the stock violently both ways. Given meaningful short interest, any mispriced headline can exacerbate moves via both panic selling and short covering.
• Operational risk and cash flow - the company carries a valuation that assumes future pipeline or deal value; absent legal wins, the company remains a clinical-stage biotech with negative EPS (~ -$0.90) and modest free cash flow (~$4.41M recently), meaning dilution risk or further capital raises could be possible and dilutive.
• Counterargument: Skeptics will say the market has already priced in most of the upside and that procedural wins are not the same as a final victory. It's reasonable to argue that the company is overvalued for a pure litigation gamble and that the stock could drift lower absent a clean legal resolution. That is why the trade uses a hard stop and a multi-month horizon: the upside is event-driven; the downside is capital preservation against an adverse legal or operational outcome.

What would change my mind

I would exit the position or reduce size materially if any of the following occur: (1) a court ruling effectively bars Anaptys from recovering royalties or significantly narrows the remedies available; (2) an unfavourable settlement that exchanges only modest cash for future rights; (3) clear signs of balance sheet stress leading to meaningful dilution; or (4) sustained deterioration in commercial prospects for Jemperli independent of the legal case, such as material negative safety or market-share news from GSK or regulators.

Closing thought

This is not a vanilla biotech play. It's a litigation-driven trade anchored to an explicit contractual lever - the Jemperli royalty waterfall. The 04/24/2026 dismissal of Tesaro’s anticipatory breach claim tightened the legal fence around Anaptys’ position and increases the probability that the company will either secure monetary relief or force a renegotiation that favors Anaptys. With a tight float, elevated short interest and a market cap that assumes outcomes but not necessarily dollars, there is an asymmetric payoff if Anaptys converts its legal option into cash flows or clear royalty economics. The trade uses disciplined risk management - entry at $52.00, stop at $45.00, target $75.00 - and a 180-trading-day horizon to let the legal process unfold and for the market to recognize value.

If you take one thing away: this is an event-driven long where legal momentum matters. Manage position size, place a firm stop, and let the litigation and any settlement process play out over the next several months.